Cerebras
CBRS
$198.71
-2.15%
Cerebras Systems Inc. designs and builds the world's fastest AI infrastructure for training and inference, centered around the largest semiconductor ever created. As a disruptive challenger to Nvidia in the AI chip market, Cerebras differentiates itself through its wafer-scale engine and integrated software stack that simplifies complex AI workloads. The stock has been highly volatile since its May 2026 IPO, with investor attention focused on its massive $25 billion backlog, partnerships with OpenAI and AWS, and the debate over whether its revenue surge can justify its lofty valuation amid ongoing losses.…
CBRS
Cerebras
$198.71
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Hold. Cerebras is a speculative growth stock with extraordinary revenue momentum but extreme valuation and ongoing losses. The analyst consensus is 'strong buy' with an average target of $291.09, but the risk/reward is balanced given the stock's proximity to its 52-week low and high volatility.
Supporting Evidence: The primary valuation metric, trailing PS of 131.3x, is far above the industry average of ~8x, but forward PS of 33.1x reflects expected revenue growth to $7.18B. Revenue grew 94.4% YoY in Q1 2026, and gross margin improved to 44.6%. TTM free cash flow is positive at $145.1M, but the company remains unprofitable with a -7.2% net margin. The implied upside to the average analyst target is 46.2%, but the low target of $209 offers only 5% upside.
Risks & Conditions: The biggest risks are valuation compression (if growth decelerates), competitive pressure from Nvidia, and continued cash burn. This Hold would upgrade to Buy if the stock pulls back below $160 (near the 52-week low) or if the company achieves sustained profitability. It would downgrade to Sell if revenue growth falls below 50% YoY or if gross margins decline below 40%. Overall, Cerebras is overvalued relative to industry peers but fairly valued relative to its own growth trajectory.
Sign up to view all
CBRS 12-Month Price Forecast
Cerebras is a high-growth, high-valuation stock with a compelling narrative but significant execution risk. The 94.4% revenue growth and $25B backlog support the bull case, but the 131x trailing PS and negative margins justify caution. The base case of steady growth to $291 is most likely, but the wide target range ($160-$340) reflects high uncertainty. An upgrade to bullish would require evidence of sustained profitability or a significant pullback in valuation. A downgrade to bearish would follow a growth deceleration below 50% or margin compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $292.00 and implied upside of +47.0% versus the current price.
Average Target
$292.00
0 analysts
Implied Upside
+47.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$209 - $340
Analyst target range
Cerebras is covered by 11 analysts, with a consensus recommendation of 'strong buy' (mean rating 1.45 on a 1-5 scale). The average target price is $291.09, implying 46.2% upside from the current price of $199.12. The distribution shows 5 analysts with Buy/Outperform ratings from recent updates (Rosenblatt, UBS, Wedbush, Morgan Stanley, Needham), all reiterating their positive stance. The target range spans from a low of $209.00 to a high of $340.00. The high target of $340 assumes continued revenue acceleration and margin expansion, potentially driven by the $25 billion backlog and partnerships with OpenAI and AWS. The low target of $209 suggests only 5% upside, pricing in risks such as gross margin compression (disappointing guidance) or competitive losses. The wide spread between low and high ($131) indicates high uncertainty, typical for a recently IPO'd high-growth company. The recent reaffirmations by major firms (Morgan Stanley, Needham) suggest conviction in the long-term story, but the stock's volatility and lack of profitability make it a high-risk, high-reward proposition.
Bulls vs Bears: CBRS Investment Factors
Cerebras presents a high-risk, high-reward opportunity. The bull case is anchored by 94.4% revenue growth, a $25B backlog, and strong analyst support with 46.2% upside to the average target. However, the bear case highlights extreme valuation (131x trailing PS), negative equity, ongoing losses, and intense competition from Nvidia. The single most important tension is whether Cerebras can convert its massive backlog into profitable, cash-flow-positive operations before its valuation premium erodes. Currently, the evidence slightly favors the bull case given the revenue trajectory and analyst consensus, but the risk of a 19%+ decline to the 52-week low is real.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue surged 94.4% YoY to $193.4M, up from $99.5M in Q1 2025, and sequential growth of 12.8% from Q4 2025's $171.4M. This dramatic acceleration signals strong demand for Cerebras' AI infrastructure.
- Massive $25B Backlog: Cerebras has a $25 billion backlog, providing multi-year revenue visibility. This backlog, combined with partnerships with OpenAI and AWS, underpins the forward PS ratio of 33.1x and analyst revenue estimates of $7.18B.
- Strong Buy Consensus: 11 analysts rate the stock a 'strong buy' with a mean rating of 1.45/5. The average target price of $291.09 implies 46.2% upside from the current $199.12, with a high target of $340 offering 70.8% upside.
- Improving Profitability Metrics: Gross margin improved to 44.6% in Q1 2026 from 31.1% in Q2 2025, and net loss narrowed to -$14M from -$23.9M a year ago. TTM free cash flow turned positive at $145.1M, indicating progress toward breakeven.
Bearish
- Extreme Valuation Premium: Trailing PS ratio of 131.3x is 1,538% above the semiconductor industry average of ~8x. Even the forward PS of 33.1x is significantly higher than peers, leaving no room for execution missteps.
- Negative Equity and High Leverage: Debt-to-equity is -0.45 due to negative equity, and ROE is -41.1%. The company relies on external financing, with $2.04B in net cash from financing in Q1 2026, raising concerns about long-term financial sustainability.
- Unprofitable Operations: Operating margin was -7.8% in Q1 2026, and net margin was -7.2%. Despite revenue growth, the company is still burning cash, with negative free cash flow of -$119.6M in Q1 2026.
- High Volatility and Downside Risk: The stock has a 45.83% maximum drawdown since its IPO and dropped 20% in a single day. With a 52-week low of $160.81, further downside could lead to a 19.2% loss from current levels.
CBRS Technical Analysis
Cerebras has been in a sustained downtrend since its IPO, with the stock price declining 20.88% from its first close to $199.12. The current price sits at 16.6% of its 52-week range (low $160.81, high $386.34), indicating it is near the bottom of its range. This positioning suggests the stock is deeply oversold and potentially offering a value opportunity, but the proximity to the 52-week low also warns of further downside risk if support fails. Short-term momentum shows a conflicting signal: the 1-month price change is +9.25%, while the 3-month change is -20.88%, indicating a recent bounce from the lows. The 1-month relative strength of 8.47% versus the S&P 500's 0.78% suggests Cerebras is outperforming the market in the short term, potentially signaling a reversal attempt. However, the divergence between the 1-month uptick and the 3-month downtrend could represent a temporary pullback within a larger downtrend, and traders should watch for confirmation of a trend change. The 52-week low at $160.81 serves as critical support, while resistance is at the 52-week high of $386.34. A breakout above $386.34 would signal a resumption of the IPO momentum, while a breakdown below $160.81 could trigger further selling. Beta data is not available, but the stock's 45.83% maximum drawdown and high volatility (e.g., 20% drop in one day post-IPO) indicate it is significantly more volatile than the market, requiring strict risk management.
Beta
—
—
Max Drawdown
-45.8%
Largest decline past year
52-Week Range
$161-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | -10.2% | +0.2% |
| 3m | — | +3.7% |
| 6m | — | +8.0% |
| 1y | — | +18.2% |
| ytd | — | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Revenue growth is accelerating dramatically: Q1 2026 revenue of $193.4 million grew 94.4% year-over-year, up from $99.5 million in Q1 2025 and $103.3 million in Q2 2025. The sequential growth from Q4 2025's $171.4 million shows a 12.8% quarter-over-quarter increase, indicating strong demand for AI infrastructure. However, the company remains unprofitable, with a net loss of $14.0 million in Q1 2026, though this loss narrowed significantly from a net loss of $23.9 million in Q1 2025. Gross margin improved to 44.6% in Q1 2026 from 31.1% in Q2 2025, but operating margin was -7.8% in Q1 2026, reflecting high R&D and SG&A costs. The net margin of -7.2% in Q1 2026 is an improvement from -24.0% in Q1 2025, but the company is still far from sustained profitability. The balance sheet shows a current ratio of 2.15 and cash of $2.75 billion, providing ample liquidity. However, debt-to-equity is -0.45 (negative equity), indicating high financial leverage. Free cash flow was -$119.6 million in Q1 2026, though trailing twelve-month free cash flow was positive at $145.1 million. ROE is -41.1%, reflecting the net loss and negative equity. The company's ability to generate positive free cash flow on a TTM basis is encouraging, but the negative equity and reliance on external financing (net cash from financing of $2.04 billion in Q1 2026) highlight financial risk.
Quarterly Revenue
$193406000.0B
2026-03
Revenue YoY Growth
+94.3%
YoY Comparison
Gross Margin
44.6%
Latest Quarter
Free Cash Flow
$145070500.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Since net income is negative (TTM net loss), we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 131.3x, while forward PS (based on estimated revenue of $7.18 billion) is approximately 33.1x. The large gap between trailing and forward PS implies the market expects massive revenue growth, which is consistent with the 94.4% YoY growth in Q1 2026. Compared to the semiconductor industry average PS ratio (typically around 5-10x), Cerebras trades at a massive premium—131x trailing PS versus an industry average of roughly 8x, a 1,538% premium. This premium is justified by the company's extraordinary growth rate and its position in the high-growth AI chip market, but it also leaves little room for error. Historically, the PS ratio has ranged from 101x (Q1 2026) to 3,077x (Q2 2023), with the current 131x near the lower end of its historical range. This suggests the stock is relatively cheap compared to its own history, but the historical range is skewed by pre-IPO periods with minimal revenue. The current PS is still extremely high by absolute standards, indicating the market is pricing in optimistic future growth.
PE
758.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
848.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cerebras faces significant financial risks due to its negative equity (debt-to-equity -0.45) and reliance on external financing ($2.04B in Q1 2026). The company is unprofitable with a net loss of $14M in Q1 2026 and negative free cash flow of -$119.6M in the same quarter. Although TTM free cash flow is positive at $145.1M, the operating margin of -7.8% indicates that the company is still spending heavily on R&D ($75.5M in Q1 2026) and SG&A. The high cash balance of $2.75B provides a cushion, but continued losses could erode liquidity if revenue growth slows.
Market & Competitive Risks: The stock trades at a massive premium to the semiconductor industry (131x trailing PS vs. ~8x industry average), making it vulnerable to valuation compression if growth disappoints. Competition from Nvidia, which has a 22x forward P/E and a dominant market position, poses a constant threat. The stock's 45.83% max drawdown and high volatility (e.g., 20% single-day drop) indicate extreme sensitivity to macro and sector sentiment. Recent news highlights that AI IPOs are historically volatile, and the stock's performance is closely tied to the broader AI investment cycle.
Worst-Case Scenario: If Cerebras fails to convert its backlog into revenue growth or faces competitive losses, the stock could fall to its 52-week low of $160.81, representing a 19.2% decline from the current price of $199.12. In a severe downturn, the stock could test lower levels, potentially losing 35% or more if the company issues disappointing guidance or loses key partnerships. The analyst low target of $209 already implies only 5% upside, suggesting limited near-term support.
FAQ
The key risks are: 1) Valuation risk: The trailing PS of 131.3x leaves no room for error; a growth slowdown could trigger a sharp de-rating. 2) Financial risk: Negative equity (debt-to-equity -0.45) and ongoing losses (net margin -7.2%) raise concerns about long-term viability. 3) Competitive risk: Nvidia dominates the AI chip market and could launch products that erode Cerebras' market share. 4) Macro risk: The stock's high volatility (45.83% max drawdown) makes it sensitive to shifts in AI spending and interest rates. The most severe risk is a 19.2% decline to the 52-week low of $160.81 if execution falters.
The 12-month forecast is highly uncertain, with three scenarios: Bull case (25% probability) targets $280-$340, driven by revenue exceeding $8B and margin expansion. Base case (50% probability) targets $209-$291, in line with analyst estimates of $7.18B revenue. Bear case (25% probability) targets $160-$209, if growth disappoints or margins compress. The most likely scenario is the base case, with the stock reaching the average analyst target of $291.09, implying 46.2% upside. However, the wide range reflects the high uncertainty typical of a recently IPO'd high-growth company.
CBRS is overvalued relative to the semiconductor industry, which trades at an average PS ratio of about 8x, compared to CBRS's trailing PS of 131.3x. However, the forward PS of 33.1x reflects the market's expectation of massive revenue growth to $7.18B. Compared to its own history, the current PS is near the lower end of its range (101x to 3,077x), suggesting it is relatively cheap by its own standards. The market is pricing in optimistic future growth, and any disappointment could lead to significant multiple compression. Overall, the stock is overvalued on an absolute basis but may be justified by its growth trajectory.
CBRS is a high-risk, high-reward stock. The analyst consensus is 'strong buy' with an average target of $291.09, implying 46.2% upside from the current price of $199.12. However, the trailing PS ratio of 131.3x is extremely high, and the company is unprofitable with a net loss of $14M in Q1 2026. The biggest downside risk is a 19.2% decline to the 52-week low of $160.81. For aggressive investors with a long-term horizon and high risk tolerance, CBRS could be a good buy if they believe in the AI infrastructure story. Conservative investors should wait for a better entry point near $160 or until the company demonstrates sustained profitability.
CBRS is more suitable for long-term investment (3-5 years) given its early stage and high volatility. The stock has a beta significantly above 1 (implied by its 45.83% max drawdown), making it risky for short-term trading. The company has a $25B backlog that provides multi-year revenue visibility, but it is not yet profitable. Short-term traders may find opportunities in the stock's volatility, but the 20% single-day drop post-IPO highlights the risks. A minimum holding period of 3 years is recommended to allow the company to execute on its backlog and achieve profitability. The stock pays no dividend, so returns depend entirely on price appreciation.